Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Tucker Kelly is recorded as CFO at Xenon Pharmaceuticals Inc. (XENE). Xenon Pharmaceuticals Inc. reported in an 8-K filed October 16, 2025 that Tucker Kelly was appointed Chief Financial Officer (CFO), effective October 15, 2025. Tucker Kelly has spoken on 1 earnings call and 2 other investor events across 1 company, most recently for Xenon Pharmaceuticals Inc. on September 9, 2026.
“Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced the appointment of Tucker Kelly as Chief Financial Officer (CFO) and member of the Xenon senior executive team.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
2025-10-15–present
Recorded roles and call appearances connecting this person to public companies.
CFO
2025-10-15–present
Other people whose current roles at this company are on record from its filings.
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
